HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis.

AbstractBACKGROUND AND PURPOSE:
Experimental autoimmune encephalomyelitis (EAE) is a widely used model of multiple sclerosis (MS) and both conditions have been reported to exhibit reduced endocannabinoid activity. The purpose of this study was to address the effect of exogenously administered 2-arachidonoylglycerol (2AG), an endocannabinoid receptor ligand, on acute phase and chronic disability in EAE.
EXPERIMENTAL APPROACH:
Acute and chronic EAE models were induced in susceptible mice and 2AG-treatment was applied for 14 days from day of disease induction.
KEY RESULTS:
2AG-treatment ameliorated acute phase of disease with delay of disease onset in both EAE models and reduced disease mortality and long-term (70 days post-induction) clinical disability in chronic EAE. Reduced axonal pathology in the chronic EAE- (p<0.0001) and increased activation and ramification of microglia in the 2AG-treated acute EAE- (p<0.05) model were noticed. The latter was accompanied by a 2- to 4-fold increase of the M2-macrophages in the perivascular infiltrations (p<0.001) of the 2AG-treated animals in the acute (day 22), although not the chronic (day 70), EAE model. Expression of cannabinoid receptors 1 (CB1R) and 2 (CB2R) was increased in 2AG-treated animals of acute EAE vs. controls (p<0.05). In addition, ex vivo viability assays exhibited reduced proliferation of activated lymph node cells when extracted from 2AG-treated EAE animals, whereas a dose-dependent response of activated lymphocytes to 2AG-treatment in vitro was noticed.
CONCLUSION AND IMPLICATIONS:
Our data indicate for the first time that 2AG treatment may provide direct (via CBRs) and immune (via M2 macrophages) mediated neuroprotection in EAE.
AuthorsAthanasios Lourbopoulos, Nikolaos Grigoriadis, Roza Lagoudaki, Olga Touloumi, Eleni Polyzoidou, Ioannis Mavromatis, Nikolaos Tascos, Aviva Breuer, Haim Ovadia, Dimitris Karussis, Ester Shohami, Raphael Mechoulam, Constantina Simeonidou
JournalBrain research (Brain Res) Vol. 1390 Pg. 126-41 (May 16 2011) ISSN: 1872-6240 [Electronic] Netherlands
PMID21406188 (Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2011 Elsevier B.V. All rights reserved.
Chemical References
  • Arachidonic Acids
  • Endocannabinoids
  • Glycerides
  • glyceryl 2-arachidonate
Topics
  • Acute Disease
  • Animals
  • Arachidonic Acids (therapeutic use)
  • Chronic Disease
  • Disease Models, Animal
  • Encephalomyelitis, Autoimmune, Experimental (drug therapy, pathology)
  • Endocannabinoids
  • Female
  • Glycerides (therapeutic use)
  • Mice
  • Mice, Inbred C57BL
  • Random Allocation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: